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There is a growing body of evidence that neural stem cells reside in the adult central nervous system where neurogenesis oc-
curs throughout lifespan. Neurogenesis concerns mainly two areas in the brain: the subgranular zone of the dentate gyrus in the
hippocampus and the subventricular zone, where it is controlled by several trophic factors and neuroactive molecules. Neuroge-
nesis is involved in processes such as learning and memory and accumulating evidence implicates hippocampal neurogenesis in
the physiopathology of depression. We herein review experimental and clinical data demonstrating that stress and antidepressant
treatments aﬀect neurogenesis in opposite direction in rodents. In particular, the stimulation of hippocampal neurogenesis by all
types of antidepressant drugs supports the view that neuroplastic phenomena are involved in the physiopathology of depression
and underlie—at least partly—antidepressant therapy.
Copyright © 2007 Eleni Paizanis et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. NEUROGENESIS
Although some occasional reports of postnatal neurogene-
sis in mammals have been published during the ﬁrst half of
the twentieth century (see [1] for a review), it was only in
the early 1960s that the ﬁrst evidence of a postnatal neuronal
proliferation was reported in various brain regions in adult
rats, including the dentate gyrus of the hippocampus [2], the
neocortex [3], and the olfactory bulb [4]. However, no con-
sensus on this adult neurogenesis was reached at this period
and these ﬁndings were somewhat forgotten for the next two
decades mainly because of their apparent lack of functional
relevance, and also because the deﬁnitive demonstration that
the adult-generated cells were neurons rather than glia was
not provided. It was only in the nineties that several techni-
cal developments allowed a clear-cut demonstration of neu-
rogenesis in adult brain. It was then established that neural
cell proliferation occurs throughout the lifespan in various
species including rodents [5], monkeys [6], and humans [7],
and is particularly important in two regions of the brain, the
dentate gyrus of the hippocampus [5, 8] and the subven-
tricular zone [9]. In the hippocampus, new granule cells are
formed from progenitors located in the hilus of the dentate
gyrus. During maturation and diﬀerentiation steps, newly
generated cells enter the granule-cell layer, migrate through
the layer towards the ﬁssure, and get integrated into the basic
circuitry of the hippocampus, notably through synaptic con-
tacts with pyramidal neurons in the CA3 ﬁeld [10, 11]. In the
subventricular zone, neurogenesis gives rise to neurons that
migrate through the rostral migratory stream and integrate
the olfactory bulb as interneurons [12, 13].
To label dividing cells, the earliest studies used [3H]-
thymidine, which incorporates into replicating DNA during
the S-phase of the cell cycle and can be detected by autora-
diography [14]. An important technical improvement was
the introduction of the synthetic thymidine analogue BrdU
(5-bromo-3-deoxyuridine) that substitutes for thymidine in
neosynthetized DNA of proliferating cells [15]. BrdU incor-
porated into DNA can then be easily visualized with im-
munocytochemical techniques using speciﬁc anti-BrdU an-
tibodies. This technique allows quantitative analysis of pro-
liferation, diﬀerentiation, and survival of newborn cells by
varying the time interval between the pulse administration
of BrdU and the sacriﬁce of animals [16–18]. The determi-
nation of the time and site of origin of newly generated cells
in the CNS requires euthanasia shortly, generally between 1
and 3 hours, after the administration of BrdU, before newly
born neurons have migrated out [19]( Figure 1).2 Neural Plasticity
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Figure 1: Photomicrograph of BrdU-positive cells in the subgran-
ular zone of the dentate gyrus 2 hours after BrdU administration in
an 8-week-old C57BL/6J mouse. Magniﬁcation: 100.
For study of cell migration, immunocytochemical label-
ing has to be performed at various post-injection times, be-
tween 4 and 10 days, and ﬁnally, the fate and survival of the
newly generated cells can be determined 21 days after BrdU
injection, once migration has been achieved [5, 10, 20, 21].
Although DNA labeling by BrdU is currently the most
commonly used method for studying adult neurogenesis, the
potential toxic eﬀect of this thymidine analogue should not
be ignored as it might be a confounding factor in some ex-
periments. This led to the use of other markers of the cell
cycle, such as proliferating nuclear antigen (PCNA) and Ki-
67, to analyze cell proliferation in situ [22] .P C N A ,ac o -
factor of DNA polymerase, is expressed during the S-phase
of cell cycle and quantiﬁcation of both PCNA- and Ki-67-
immunopositive cells has been shown to reliably reﬂect cel-
lular proliferation, like BrdU labeling, in the adult DG [23].
Intherodentbrain,approximately9000newneuronsper
day (i.e., 270 000 per month) are generated [24], and survive
with a half-life of approximately 28 days [25]. This constitu-
tive neurogenesis declines with age, as evidenced in rodents
[26] and rhesus monkeys [27]. Although earliest studies on
songbirds provided data in support of a functional role of
adult neurogenesis in seasonal song learning [28], the possi-
ble functional signiﬁcance of this process remains to be for-
mally determined in mammals. However, the fact that hip-
pocampal neurogenesis can be modulated by various fac-
torsincludinghormones,neurotransmitters,orenvironment
suggestsitsrealimplicationinphysiologicalmechanismsand
not its occurrence as a nonfunctional residual phenomenon
in mammals [29]. In particular, glucocorticoids (including
cortisol) have been shown to exert a negative inﬂuence that
may account for the marked reduction in granule cell pro-
liferation caused by stress [30], whereas, in contrast, antide-
pressant treatments markedly stimulate hippocampal neuro-
genesis [31]. The relevance of these data for pathophysiolog-
ical mechanisms underlying depression is critically analyzed
in the following section.
2. STRESS, GLUCOCORTICOIDS,AND NEUROGENESIS
Numerous studies have emphasized that stress can be the
most signiﬁcant causal agent, together with genetic vulner-
ability, in the etiology of depression. In addition, neurons in
the hippocampal formation are among the most sensitive to
the deleterious eﬀects of stress. Consequently, stress-induced
decrease in hippocampal neurogenesis might be an impor-
tant feature associated with depression episodes.
Stress may be caused by any environmental change,
whether internal or external, that disrupts the maintenance
of homeostasis, and initiates a series of neuronal responses
to prepare the organism to adapt to this new environmen-
tal challenge. Under environmental or psychological stress-
fulconditions,neuronsintheparaventricularnucleus(PVN)
of the hypothalamus secrete corticotropin-releasing hor-
mone/factor (CRH/CRF) and arginine-vasopressin (AVP),
which in turn, stimulate the secretion of adrenocorticotropic
hormone (ACTH) from the anterior pituitary gland. ACTH
promotes the synthesis and the release of glucocorticoids
fromtheadrenalcortexwhichallowstheappropriateadapta-
tion of the organism to stress, mainly through their vascular
and metabolic eﬀects [32].
The principal glucocorticoids are cortisol in humans and
corticosterone in rodents. They both inﬂuence metabolism,
cognitive processes, and emotions, especially fear and anx-
iety. To prevent deleterious eﬀects of excessive levels of cir-
culatingglucocorticoids,thehypothalamic-pituitary-adrenal
( H P A )s t r e s sa x i si su n d e rt i g h tc o n t r o l[ 32] through miner-
alocorticoid(MR)andglucocorticoid(GR)receptornegative
feedback regulation [33]. Chronic stress frequently results in
glucocorticoid and CRF hypersecretion associated with de-
creasedsensitivitytoglucocorticoid-mediatedfeedbackinhi-
bition. In vulnerable individuals, chronic stress may lead to
excessively long lasting HPA responses that may precipitate
psychopathologies such as anxiety and depression [34, 35].
Both basic and clinical studies have shown that stress can
be associated with morphometric brain changes, neuronal
atrophy, and decrease in the proliferation of progenitor cells
in the hippocampal dentate gyrus. Whether these modiﬁca-
tions really contribute to the development of depression is
still a matter of debate [31, 36–39].
During the last decade, a series of reports indicated that
major depression is frequently associated with signiﬁcant at-
rophy within the hippocampus, which can persist for sev-
eral years after remission from depression episodes [40–42].
In addition, prolonged depressions appeared to be associ-
ated with more severe atrophy [43]. Since the hippocampusEleni Paizanis et al. 3
plays a central role in learning and memory, these data sug-
gested that such morphological alterations might be related
to the cognitive deﬁcits observed during depressive episodes
[44, 45]. More recently, Stockmeier et al. [46]r e p o r t e dar e -
duction in both the average soma size of pyramidal neurons
and neuropil, which may contribute to the volume retrac-
tion noted using fMRI in the hippocampus of patients with
major depressive disorders. These morphometric alterations
aremostoftenattenuatedorevenreversedbyantidepressants
[46, 47].
Extensive preclinical investigations recently provided
some keys toward understanding biological mechanisms
causally related to hippocampus atrophy in severely de-
pressed patients. In rodents, adrenal steroids were the ﬁrst
endogenous compounds to be identiﬁed as factors aﬀecting
hippocampal neurogenesis [48]. To date, adrenal steroids are
well known to regulate both proliferation and diﬀerentiation
of new neurons in the dentate gyrus [49]. In rats, a sustained
increase in plasma corticosterone causes a decrease in neuro-
genesis while, reciprocally, adrenalectomy increases this pro-
cess [50]. Indeed, removal of the adrenals accelerates neural
cell proliferation and delays the death of newly formed neu-
rons. Giving excess corticoids (e.g., corticosterone) has con-
verse eﬀects and consequently decreases the formation and
survival of progenitor cells [51]. Treatment of adult male rats
for21dayswithexogenousglucocorticoidshasalsoaremod-
eling eﬀect on dendrites in hippocampal neurons [52, 53].
In congruence with observations in depressed patients,
both a reduction in hippocampal volume and a decrease in
neurogenesis have been reported in subordinate tree shrews
subjectedtosocialinteractionstress,whichconsistsofadaily
psychosocial conﬂict by introducing a naive animal into the
cage of a socially experienced one [54, 55]. Changes in cell
morphology, apical dendrite length, and branching of CA3
pyramidal cells were also observed in the same species under
closely related experimental conditions [56]. Furthermore,
chronic restraint stress for 21 days in rats led apical dendrites
of CA3 pyramidal neurons to atrophy [57] and strongly re-
duced proliferation of dentate gyrus precursor cells [58].
Prenatal stress also decreases neurogenesis in the adult hip-
pocampusalongwithincreasedanxiety-likebehavior,hyper-
activity of HPA axis, and reduced learning ability in rats [59]
andexacerbatedemotionalbehaviorinrhesusmonkeys[60].
On the other hand, inescapable stress leads to a reduction
in neurogenesis that correlates with behavioral despair sev-
eral days after exposure to stress in the learned helplessness
model of depression [61]. Very recently, chronic mild stress,
a validated paradigm to induce depression-like symptoms,
has been shown to decrease survival (but not proliferation)
of new born cells in adult rat hippocampus [62].
3. SEROTONIN, ANTIDEPRESSANTS, AND
NEUROGENESIS
Serotonin, a key regulator of cell division, has been shown to
modulatediﬀerentprocessessuchasneurogenesis,apoptosis,
axon branching, and dendritogenesis during brain develop-
ment [63]. This leads to propose for this neurotransmitter a
critical role in the control of adult neural cell proliferation.
In adult rats, the ﬁrst study aimed at assessing the eﬀect of 5-
HT on neurogenesis was carried out using d,l-fenﬂuramine,
which releases 5-HT throughout the central nervous system.
Thus, Jacobs et al. [64] noted that d,l-fenﬂuramine increased
cell division by two- to three-fold in the dentate gyrus. Sub-
sequent studies conﬁrmed the proliferating eﬀect of 5-HT
within the subgranular zone of the dentate gyrus [65], where
both progenitor cells and a dense innervation by seroton-
ergic ﬁbers are observed [66]. Furthermore, a decrease in
5-HT content after either a lesion of serotonergic neurons
by 5,7-dihydroxytryptamine (5,7-DHT) [67] or an inhibi-
tion of 5-HT synthesis by parachlorophenylalanine (PCPA)
[67, 68] produced long-term deﬁcits in the proliferation of
hippocampal cells, and raphe grafts (which are enriched in
5-HT-producing neurons) reversed these deﬁcits, very prob-
ably by replenishing endogenous 5-HT stores and restoring
5-HT functions [69].
The preferential involvement of 5-HT1A receptors in the
5-HT eﬀects on cell proliferation was ﬁrst suggested by Ja-
cobs et al. [64], who showed that d,l-fenﬂuramine -induced
increase in neurogenesis was prevented by the selective 5-
HT1A receptor antagonist, WAY 100635. Later on, the pro-
moting eﬀect of 5-HT1A receptor activation on hippocampal
neurogenesis was conﬁrmed by other groups. In particular,
Santarelli et al. [70] noted that the 5-HT1A receptor agonist,
8-OH-DPAT, caused an increase in cell proliferation in wild-
type mice, but was ineﬀective in 5-HT1A receptor knock-out
mice, indicating that the action of 8-OH-DPAT was entirely
mediated by 5-HT1A receptors. However, other types of sero-
tonergic receptors were also shown to be involved in the ef-
fects of serotonin on hippocampal cell proliferation. This is
notablythecaseof5-HT2A and5-HT2C receptorswhoseacti-
vation by selective agonists enhanced neurogenesis in the rat
dentate gyrus [65]. A simulatory eﬀect was also noted with
5-HT1B receptor agonists but only after 5-HT depletion [65].
Whetherreceptorsofthe5-HT4,5-HT6,and5-HT7 typesare
also implicated in the regulation of hippocampal neurogen-
esis is still an open question to be addressed.
The clinical beneﬁt of antidepressants that increase sero-
tonergic neurotransmission such as selective serotonin reup-
take inhibitors (SSRIs) drove several teams to analyze the
eﬀects of these drugs on cell proliferation and neurogene-
sis. A three-week systemic treatment with ﬂuoxetine was ﬁrst
found to increase by 70 percent cell proliferation in the den-
tate gyrus in rodents [30, 31]. Because this eﬀect was not
observed in 5-HT1A receptor knock-out mice, it could be
inferred that 5-HT1A receptor activation actually mediated
ﬂuoxetine-induced neurogenesis [71]. Several groups then
conﬁrmed that chronic, but not acute, antidepressant treat-
ments exert a stimulatory inﬂuence on hippocampal neu-
rogenesis [38, 61, 72]. Interestingly, all classes of antide-
pressant drugs tested so far, including NA and 5-HT reup-
take inhibitors [30], atypical antidepressants such as tianep-
tine [54], electroconvulsive seizures, mood stabilizers such as
lithium[31,73],wereshowntoincreasetheproliferationand
survival of new neurons in the dentate gyrus.4 Neural Plasticity
The lack of antidepressant-like eﬀect of ﬂuoxetine in x-
irradiated mice, in which neurogenesis was abolished, led
to the claim that clinical eﬀectiveness of antidepressants is
directly related to their promoting eﬀect on hippocampal
cell proliferation [71]. Interestingly, chronic treatments with
CRH-R1 and V1b receptor antagonists, which are endowed
with antidepressant-like properties in validated animal mod-
els [74, 75], also exerted a positive inﬂuence on hippocam-
pal granule cell proliferation, thereby reversing the reduc-
tion in this process which had been caused by chronic mild
stress [76]. Furthermore, the new antidepressant agomela-
tine also exerts a stimulatory inﬂuence on cell prolifera-
tionwithinthehippocampus.Chronicadministrationofthis
mixed MT1/MT2 melatonin receptor agonist and 5-HT2B/2C
receptor antagonist signiﬁcantly increased the number of
new born cells in the hippocampus of adult rats [77], and re-
versed the deﬁcit in granule cell proliferation that had been
induced at adult stage in rats born from a mother subjected
to repeated stress during gestation [78]. In line with these
observations, preliminary data from our laboratory showed
that chronic treatment with ﬂuoxetine or agomelatine com-
pensated for the deﬁcit in neurogenesis observed in trans-
genic GR-i mice (a murine model of depression, [79]), and
raised this process up to the level observed in healthy paired
wild-type mice [80]. These data are compatible with the idea
that all types of antidepressant treatments apparently share
thecapacitytoenhancecellproliferationandneurogenesisin
the dentate gyrus of the hippocampus, thereby antagonizing
the reductionin this processthathas been regularly observed
invalidatedanimalmodelsofdepression(GR-imice,learned
heplessness, genetically helpless mice, chronic psychosocial
stress, etc.) and is very likely occurring also in patients dur-
ing a severe depression episode.
5-HT and corticotrope systems are closely cross-
regulated under normal physiological conditions in mam-
mals [81, 82] and their interactions are of particular rele-
vance when considering pathological conditions such as de-
pression, in which dysfunctioning of both systems has been
consistently documented [83–86]. Although the exact mech-
anisms by which stress and glucocorticoids on the one hand,
and antidepressants and serotonin on the other hand, aﬀect
neurogenesis have not been completely elucidated, evidence
has been reported that modiﬁcations in the expression of
brain-derived neurotrophic factor(BDNF) in the hippocam-
pus might be part of the causal event [87]. BDNF is a major
neurotrophicfactorinbrain,whichplayskeyrolesinthesur-
vival and guidance of neurons during development, and is
required for the survival and normal functioning of neurons
intheadultbrain[88].DecreasedlevelsofBDNFinresponse
to stress could lead to a loss of normal plasticity and also to
damage and death of neurons. It is conceivable that the cell
loss observed in depression could result from alterations in
factors that control programmed cell death including cAMP
response element binding (CREB) protein. Indeed, Dowlat-
shahi et al. [89] reported that CREB levels are decreased in
the cerebral cortex of depressed patients. Conversely, several
studies demonstrated that antidepressant treatment upregu-
lates cAMP production, and, in turn, the CREB cascade in-
cluding CREB-induced expression of BDNF [90]. Interest-
ingly, upregulation of CREB and BDNF occurs not only in
response to chronic treatment with various classes of an-
tidepressant drugs, including NA and/or 5-HT reuptake in-
hibitors, but also after electroconvulsive seizures mimicking
electroconvulsivetherapy.Accordingly,itcanbeinferredthat
the cAMP-CREB cascade and BDNF are common postrecep-
tor targets of both glucocorticoids and antidepressant treat-
ments [70, 91] and thus very probably participate in associ-
ated neuroplastic phenomena.
4. CONCLUSION
The data summarized in this review highlight the involve-
ment of hippocampal plasticity in physiopathological pro-
cesses linked to mood disorders. Both corticotrope and sero-
tonin systems have largely been involved in depressive symp-
toms and most of the eﬀective antidepressant therapies are
known to act through them. Interestingly, these two sys-
tems induce sustained modiﬁcations in adult hippocam-
pal neurogenesis. However, much remains to be understood
about the relations between cell proliferation, the hippocam-
pus, and depression. Although hippocampal neurogenesis
appears to be necessary for antidepressant drugs to allevi-
ate depression-related behavioral deﬁcits, it is probably not
the case for the positive behavioral eﬀects of environmental
enrichment [92] and the antidepressant therapy using tran-
scranial magnetic stimulation [93]. Accordingly, relation-
ships between cell proliferation and antidepressant therapy
are probably much more complex than originally claimed.
However, the observation that cell proliferation parallels the
eﬀects of antidepressant drugs may lead to set up new strate-
gies to treat depressive disorders. To this aim, elucidating
the cellular and molecular mechanisms of action of antide-
pressants on neurogenesis is the further critical steps to be
achieved.
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